CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.6589
5.73%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0355
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

AcelRx Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.6978
Open* 0.7079
1-Year Change* 202.78%
Day's Range* 0.6478 - 0.7179
52 wk Range 0.16-0.95
Average Volume (10 days) 589.82K
Average Volume (3 months) 46.02M
Market Cap 31.41M
P/E Ratio 0.74
Shares Outstanding 147.33M
Revenue 2.88M
EPS 0.29
Dividend (Yield %) N/A
Beta 0.45
Next Earnings Date Nov 14, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 22, 2023 0.6578 -0.0501 -7.08% 0.7079 0.7180 0.6478
Sep 21, 2023 0.6978 -0.0500 -6.69% 0.7478 0.7578 0.6496
Sep 20, 2023 0.7398 -0.0380 -4.89% 0.7778 0.8305 0.7398
Sep 19, 2023 0.7977 -0.0251 -3.05% 0.8228 0.8278 0.7678
Sep 18, 2023 0.8227 -0.0551 -6.28% 0.8778 0.9128 0.7988
Sep 15, 2023 0.8878 0.0000 0.00% 0.8878 0.8979 0.8503
Sep 14, 2023 0.8878 0.0900 11.28% 0.7978 0.8978 0.7878
Sep 13, 2023 0.8364 -0.0483 -5.46% 0.8847 0.8982 0.8078
Sep 12, 2023 0.8693 0.0815 10.35% 0.7878 0.9079 0.7878
Sep 11, 2023 0.7779 -0.0899 -10.36% 0.8678 0.8678 0.7642
Sep 8, 2023 0.8481 0.0020 0.24% 0.8461 0.8847 0.8461
Sep 7, 2023 0.8761 -0.0703 -7.43% 0.9464 0.9464 0.8461
Sep 6, 2023 0.9252 -0.0391 -4.05% 0.9643 0.9643 0.8962
Sep 5, 2023 0.9661 -0.0500 -4.92% 1.0161 1.0461 0.9367
Sep 1, 2023 1.0261 0.0000 0.00% 1.0261 1.0461 0.9648
Aug 31, 2023 1.0261 0.0300 3.01% 0.9961 1.0761 0.9961
Aug 30, 2023 1.0261 0.1100 12.01% 0.9161 1.0261 0.9111
Aug 29, 2023 0.9501 0.0615 6.92% 0.8886 0.9861 0.8461
Aug 28, 2023 0.9161 -0.1000 -9.84% 1.0161 1.0561 0.8204
Aug 25, 2023 1.0861 -0.0200 -1.81% 1.1061 1.1061 1.0261

AcelRx Events

Time (UTC) Country Event
Tuesday, October 10, 2023

Time (UTC)

17:00

Country

US

Event

AcelRx Pharmaceuticals Inc Annual Shareholders Meeting
AcelRx Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, November 13, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 AcelRx Pharmaceuticals Inc Earnings Release
Q3 2023 AcelRx Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 2.818 5.416 2.289 2.151 7.995
Revenue 2.818 5.416 2.289 2.151 7.995
Cost of Revenue, Total 3.753 6.032 6.806 3.976 10.659
Gross Profit -0.935 -0.616 -4.517 -1.825 -2.664
Total Operating Expense 38.783 46.379 56.494 37.878 46.677
Selling/General/Admin. Expenses, Total 30.935 36.33 45.027 20.765 16.609
Research & Development 4.095 4.017 4.661 13.137 19.409
Unusual Expense (Income) 0
Operating Income -35.965 -40.963 -54.205 -35.727 -38.682
Interest Income (Expense), Net Non-Operating -2.167 -2.722 -0.369 -1.079 -2.806
Other, Net 3.038 3.31 1.337 -10.341 -10.721
Net Income Before Taxes -35.094 -40.375 -53.237 -47.147 -52.209
Net Income After Taxes -35.099 -40.379 -53.24 -47.149 -17.405
Net Income Before Extra. Items -35.099 -40.379 -53.24 -47.149 -17.405
Net Income -35.099 -40.379 -53.24 -47.149 -51.508
Income Available to Common Excl. Extra. Items -35.099 -40.379 -53.24 -47.149 -17.405
Income Available to Common Incl. Extra. Items -35.099 -40.379 -53.24 -47.149 -51.508
Diluted Net Income -35.099 -40.379 -53.24 -47.149 -51.508
Diluted Weighted Average Shares 119.86 85.257 79.1843 58.4086 46.8835
Diluted EPS Excluding Extraordinary Items -0.29283 -0.47362 -0.67236 -0.80723 -0.37124
Diluted Normalized EPS -0.29387 -0.47362 -0.67236 -0.80723 -0.37124
Total Extraordinary Items 0 -34.103
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 0.442 0.002 1.862 0.443 0.511
Revenue 0.442 0.002 1.862 0.443 0.511
Cost of Revenue, Total 0.784 1.234 0.439 1.04 1.04
Gross Profit -0.342 -1.232 1.423 -0.597 -0.529
Total Operating Expense 9.437 8.177 10.495 10.458 9.653
Selling/General/Admin. Expenses, Total 7.338 5.957 8.64 8.694 7.644
Research & Development 1.315 0.986 1.416 0.724 0.969
Operating Income -8.995 -8.175 -8.633 -10.015 -9.142
Interest Income (Expense), Net Non-Operating -0.352 -0.435 -0.506 -0.63 -0.596
Other, Net 0.673 0.693 0.764 0.799 0.782
Net Income Before Taxes -8.674 -7.917 -8.375 -9.846 -8.956
Net Income After Taxes -8.674 -7.917 -8.375 -9.851 -8.956
Net Income Before Extra. Items -8.674 -7.917 -8.375 -9.851 -8.956
Net Income -8.674 -7.917 -8.375 -9.851 -8.956
Income Available to Common Excl. Extra. Items -8.674 -7.917 -8.375 -9.851 -8.956
Income Available to Common Incl. Extra. Items -8.674 -7.917 -8.375 -9.851 -8.956
Diluted Net Income -8.674 -7.917 -8.375 -9.851 -8.956
Diluted Weighted Average Shares 145.624 127.774 119.224 119.12 113.257
Diluted EPS Excluding Extraordinary Items -0.05956 -0.06196 -0.07025 -0.0827 -0.07908
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.05956 -0.06196 -0.07025 -0.08089 -0.08369
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 55.489 46.83 71.688 107.994 63.413
Cash and Short Term Investments 51.63 42.886 66.137 105.715 60.469
Cash & Equivalents 12.663 27.274 14.684 87.975 52.902
Short Term Investments 38.967 15.612 51.453 17.74 7.567
Total Receivables, Net 0.16 0.635 0.52 0.401 1.533
Accounts Receivable - Trade, Net 0.16 0.635 0.432 0.049 1.533
Total Inventory 1.111 1.626 3.295 0.854 0.956
Prepaid Expenses 2.588 1.683 1.736 1.024 0.455
Total Assets 77.893 66.295 91.356 120.533 75.552
Property/Plant/Equipment, Total - Net 20.23 18.809 18.48 11.483 11.051
Property/Plant/Equipment, Total - Gross 31.016 29.398 28.032 20.427 19.489
Accumulated Depreciation, Total -10.786 -10.589 -9.552 -8.944 -8.438
Other Long Term Assets, Total 2.174 0.656 0.925 0.705 0.385
Total Current Liabilities 18.509 17.635 13.611 15.928 13.66
Accounts Payable 2.121 2.737 1.72 2.07 1.424
Accrued Expenses 7.506 6.008 6.498 4.54 3.543
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 8.796 8.841 4.982 9.003 8.331
Other Current Liabilities, Total 0.086 0.049 0.411 0.315 0.362
Total Liabilities 113.786 122.045 132.774 116.28 112.061
Total Long Term Debt 5.007 13.14 20.517 3.38 11.369
Long Term Debt 5.007 13.14 20.517 3.38 11.369
Other Liabilities, Total 90.27 91.27 98.646 96.972 87.032
Total Equity -35.893 -55.75 -41.418 4.253 -36.509
Common Stock 0.137 0.098 0.079 0.078 0.051
Additional Paid-In Capital 437.554 382.637 356.609 349.194 261.31
Retained Earnings (Accumulated Deficit) -473.584 -438.485 -398.106 -345.019 -297.87
Other Equity, Total 0
Total Liabilities & Shareholders’ Equity 77.893 66.295 91.356 120.533 75.552
Total Common Shares Outstanding 136.82 98.812 79.5731 78.7579 50.8992
Note Receivable - Long Term 0.263 0.351 0.703
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 42.811 55.489 51.753 58.97 71.315
Cash and Short Term Investments 39.349 51.63 48.699 55.325 67.345
Cash & Equivalents 21.822 12.663 13.271 26.327 34.363
Short Term Investments 17.527 38.967 35.428 28.998 32.982
Total Receivables, Net 0.184 0.16 0.153 0.104 0.658
Accounts Receivable - Trade, Net 0.184 0.16 0.153 0.104 0.658
Total Inventory 1.045 1.111 1.556 1.363 1.419
Prepaid Expenses 2.233 2.588 1.345 2.178 1.893
Total Assets 71.971 77.893 72.263 79.586 87.347
Property/Plant/Equipment, Total - Net 20.08 20.23 20.229 20.546 15.962
Other Long Term Assets, Total 0.261 2.174 0.281 0.07 0.07
Total Current Liabilities 17.033 18.509 17.07 15.188 15.544
Accounts Payable 2.715 2.121 2.228 1.941 3.235
Accrued Expenses 5.505 7.592 6.062 4.483 3.528
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 8.813 8.796 8.78 8.764 8.781
Other Current Liabilities, Total 0
Total Liabilities 110.244 113.786 115.284 115.575 114.659
Total Long Term Debt 3.041 5.007 6.952 9.374 11.265
Long Term Debt 3.041 5.007 6.952 9.374 11.265
Other Liabilities, Total 90.17 90.27 91.262 91.013 87.85
Total Equity -38.273 -35.893 -43.021 -35.989 -27.312
Common Stock 0.147 0.137 0.119 0.119 0.118
Additional Paid-In Capital 443.838 437.554 422.527 421.184 420.011
Retained Earnings (Accumulated Deficit) -482.258 -473.584 -465.667 -457.292 -447.441
Total Liabilities & Shareholders’ Equity 71.971 77.893 72.263 79.586 87.347
Total Common Shares Outstanding 147.109 136.82 119.317 119.18 119.103
Intangibles, Net 8.819
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -35.099 -40.379 -53.24 -47.149 -51.508
Cash From Operating Activities -30.002 -38.505 -51.18 -29.075 -29.765
Cash From Operating Activities 1.973 1.853 1.668 0.575 1.744
Non-Cash Items 2.921 2.309 4.298 15.632 16.3
Cash Taxes Paid 0.005 -0.347 -0.35 0.002 0.002
Cash Interest Paid 1.595 2.269 1.712 1.667 2.043
Changes in Working Capital 0.203 -2.288 -3.906 1.867 3.699
Cash From Investing Activities -26.123 34.139 -36.563 -10.877 -9.97
Capital Expenditures -1.827 -1.855 -3.47 -0.819 -2.405
Other Investing Cash Flow Items, Total -24.296 35.994 -33.093 -10.058 -7.565
Cash From Financing Activities 41.514 16.956 14.452 75.025 12.327
Financing Cash Flow Items 5.313 -0.086 -9.054 0 -0.204
Issuance (Retirement) of Stock, Net 45.034 21.709 1.976 82.743 16.045
Issuance (Retirement) of Debt, Net -8.833 -4.667 21.53 -7.718 -3.514
Net Change in Cash -14.611 12.59 -73.291 35.073 -27.408
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -8.674 -35.099 -27.182 -18.807 -8.956
Cash From Operating Activities -8.934 -30.002 -21.998 -18.055 -9.708
Cash From Operating Activities 0.42 1.973 1.512 1.029 0.45
Non-Cash Items 0.246 2.921 1.75 0.966 0.03
Changes in Working Capital -0.926 0.203 1.922 -1.243 -1.232
Cash From Investing Activities 20.176 -26.123 -21.684 -15.032 -17.425
Capital Expenditures -0.089 -1.827 -1.799 -1.615 -0.024
Other Investing Cash Flow Items, Total 20.265 -24.296 -19.885 -13.417 -17.401
Cash From Financing Activities -2.083 41.514 29.679 32.14 34.222
Financing Cash Flow Items -0.058 5.313 -0.249 -0.249 -0.249
Issuance (Retirement) of Stock, Net 0.058 45.034 36.678 36.556 36.554
Issuance (Retirement) of Debt, Net -2.083 -8.833 -6.75 -4.167 -2.083
Net Change in Cash 9.159 -14.611 -14.003 -0.947 7.089

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AcelRx Company profile

AcelRx
Industry: Bio Therapeutic Drugs

25821 Industrial Boulevard
Suite 400
94545

Income Statement

  • Annual
  • Quarterly

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

Oil - Crude

90.14 Price
+0.770% 1D Chg, %
Long position overnight fee 0.0415%
Short position overnight fee -0.0634%
Overnight fee time 21:00 (UTC)
Spread 0.030

ETH/USD

1,596.49 Price
+0.120% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

BTC/USD

26,624.10 Price
+0.150% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

XRP/USD

0.51 Price
-0.840% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading